# MeiraGTx (MGTX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/MGTX
## Company Profile
- Ticker: MGTX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United Kingdom with U
- Tags: Gene Therapy, Rare Disease Gene Therapy, Inherited Retinal Disease Gene Therapy, Rare Disease, Ophthalmology
## Stock Data
- Close: 13.97 USD
- Market cap: 855711927.84 USD
- Last updated: 2026-09-03
## Business Overview
### Genetic Medicines Company
MeiraGTx develops and manufactures gene therapies for inherited retinal disease, salivary-gland disorders, and other conditions. Its vertically integrated model spans vector design, clinical development, and commercial manufacturing.
### Bota-Vec
Botaretigene sparoparvovec is an AAV gene therapy for X-linked retinitis pigmentosa caused by RPGR mutations. MeiraGTx acquired global rights after completion of the Phase 3 LUMEOS study.
### AAV2-hAQP1
AAV2-hAQP1 delivers the aquaporin-1 water-channel gene to salivary glands as a treatment for radiation-induced xerostomia. The program has received FDA Breakthrough Therapy designation.
### Riboswitch Platform
MeiraGTx's Riboswitch technology is designed to regulate therapeutic-protein production with an oral small molecule after gene delivery. Initial programs include metabolic disease and neuropathic pain.
### Manufacturing Infrastructure
The company operates gene-therapy manufacturing and quality-control facilities intended to support regulatory filings and potential commercial launches.
## Why The Stock Is Moving

As of Sep 3, 2026, MGTX closed down 0.64% at $13.97. No new same-company headline was identified in the current news window.

## Future Catalysts

- Global regulatory filings for bota-vec in X-linked retinitis pigmentosa during 2026.
- Potential commercial launch of bota-vec in 2027, subject to approval.
- Potential BLA submission for AAV2-hAQP1 in radiation-induced xerostomia in mid-2027.

## Recent News
- 2026-08-13 12:00 EST — [MeiraGTx Reports Second Quarter 2026 Financial and Operational Results](https://biopharmsignal.com/news/MGTX/meiragtx-reports-second-quarter-2026-financial-and-operational-results-7f83916b) — Source: MeiraGTx
- 2026-08-06 20:30 EST — [MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/MGTX/meiragtx-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-3ee9d0a1) — Source: MeiraGTx
- 2026-07-07 11:30 EST — [MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)](https://biopharmsignal.com/news/MGTX/meiragtx-announces-400-million-strategic-investment-by-oberland-capital-to-suppo-b21561a1) — Source: MeiraGTx
- 2026-05-14 12:00 EST — [MeiraGTx Reports First Quarter 2026 Financial and Operational Results](https://biopharmsignal.com/news/MGTX/meiragtx-reports-first-quarter-2026-financial-and-operational-results) — Source: MeiraGTx
- 2026-04-16 11:48 EST — [MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares](https://biopharmsignal.com/news/MGTX/meiragtx-announces-pricing-of-100-million-offering-of-ordinary-shares) — Source: MeiraGTx